VEGF and ANG-2 — Drug Target
All drugs that target VEGF and ANG-2 — marketed and clinical-stage. Includes 1 drug classes acting on this target.
Drug classes
Phase 3 pipeline (1)
- KSI-101 · Kodiak Sciences Inc · Bispecific antibody · Ophthalmology
KSI-101 is a bispecific antibody that simultaneously targets VEGF and ANG-2 to reduce retinal inflammation and vascular leakage in retinal diseases.